EXETER, N.H.--(BUSINESS WIRE)--CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that its Board of Directors is continuing its previously announced process to review strategic alternatives to maximize shareholder value. The strategic alternatives the Board of Directors is reviewing include, but are not limited to, a sale, merger or other business combination of CPEX with a third party or a monetization of CPEX’s assets including its rights to receive royalties and milestone payments.
